Italian pharma Menarini Group has licensed European rights to bofanglutide for obesity and excess weight, a long-acting GLP-1 receptor agonist from China’s Gan & Lee Pharmaceuticals dosed once every two weeks, for €62 million upfront, up to €664 million in milestones, and “double-digit” royalties. Menarini will handle regulatory submissions and commercialization across 39 European markets.
Remote Bioprocess Monitoring with BioNsight® cloud: Every run in one view, from 100 mL development to production
ProductsNovartis commits $3.2B to subcutaneous delivery
Latest NewsNovartis could pay up to $3.223 billion (€2.8 billion) for access to Alteogen’s technology for turning intravenous biologics into subcutaneous drugs. Behind the eye-catching figure is more than patient convenience: Drug delivery is becoming an increasingly important tool for lifecycle management and emerging drug classes.
Menarini pays up to €726M for Chinese obesity drug
Latest NewsItalian pharma Menarini Group has licensed European rights to bofanglutide for obesity and excess weight, a long-acting GLP-1 receptor agonist from China’s Gan & Lee Pharmaceuticals dosed once every two weeks, for €62 million upfront, up to €664 million in milestones, and “double-digit” royalties. Menarini will handle regulatory submissions and commercialization across 39 European markets.
Transgene cancer vaccine keeps patients relapse-free for three years
Latest NewsFrench biotech Transgene said all 16 head and neck cancer patients treated with its personalized cancer vaccine TG4050 in a randomized Phase 1 trial remained disease-free after three years, while three of 16 patients in the control arm relapsed.
GSK bets $1.3B on KRAS-EGFR conjugate from HUTCHMED
Latest NewsGSK has licensed ex-China rights to HUTCHMED’s HMPL-A830, an experimental antibody conjugate that delivers a KRAS inhibitor to EGFR-expressing tumors, in a deal worth up to $1.295 billion (€1.12 billion). The preclinical asset is expected to enter the clinic this year.
NovaGo raises $30M to advance regenerative spinal cord therapy
Latest NewsSwiss biotech NovaGo Therapeutics has raised CHF 24 million ($30 million/€25.5 million) in a Series B round to advance its lead anti-Nogo-A antibody into a randomized proof-of-concept study in patients with acute spinal cord injury. The financing was co-led by Neurimmune and Pureos, with participation from existing and new investors. The round is complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life.
Novartis breaks BTK losing streak in multiple sclerosis
Latest NewsNovartis’ remibrutinib has beaten teriflunomide in two Phase 3 trials in relapsing multiple sclerosis (MS), adding another important clinical win for a class of BTK inhibitors that has endured several high-profile failures in autoimmune disease.
Roche reloads B-cell strategy with $1.53B Simcere deal
Latest NewsRoche has licensed Simcere Zaiming’s preclinical trispecific antibody SIM0660, paying $75 million (€65 million) upfront in a deal potentially worth $1.53 billion (€1.32 billion).
Amyl Tx raises €8.25M to develop universal neurodegeneration drug
Latest NewsBelgian biotech Amyl Therapeutics has completed an €8.25 million Series A extension to fund work on its universal treatment for neurodegenerative diseases.
Adaptyv raises $40M for AI-run wet labs
Latest NewsSwiss biotech Adaptyv has raised a $40 million (€34.5 million) Series A to expand its automated protein-testing labs, betting that wet-lab capacity will become a critical bottleneck as AI models generate ever more biological designs.